The Dry Eye Chronicles by Kala Pharmaceuticals

EPISODE 5 : Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye (PART 2) Preeya Gupta, MD & Christopher Starr, MD, FACS With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Christopher Starr, MD, joins Preeya Gupta, MD, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

EPISODE 5 : Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye (PART 1) Preeya Gupta, MD & Christopher Starr, MD, FACS With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Christopher Starr, MD, joins Preeya Gupta, MD, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

Episode 5 - Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye Part 2 (OD) Walt Whitley, OD, MBA, FAAO, & Marc Bloomenstein, OD, FAAO With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Dr. Marc Bloomenstein, OD, FAAO joins Walt Whitley, OD, MBA, FAAO, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

Episode 5 - Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye Part 1 (OD) Walt Whitley, OD, MBA, FAAO, & Marc Bloomenstein, OD, FAAO With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Dr. Marc Bloomenstein, OD, FAAO joins Walt Whitley, OD, MBA, FAAO, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

EPISODE 4: Thinking Differently: An In-Depth Look at Dry Eye Flares Preeya Gupta, MD, & Sarah Darbandi, MD Most of us, including many clinicians, can get lost in the forest for the trees when trying to understand Dry Eye and Dry Eye Flares. With up to 70-80% of Dry Eye patients in some practices suffering from Dry Eye Flares, it's important for practitioners to understand where these numbers are coming from, and what they can do to lower them. In this podcast, Dr. Sarah Darbandi, MD, joins Preeya Gupta, MD, to discuss the importance of communication surrounding triggers and treatment options with patients, as well as keeping practitioners up-to-date with the current literature to better understand the pathophysiology of the condition.

EPISODE 4: Thinking Differently: An In-Depth Look at Dry Eye Flares Walt Whitley, OD, MBA, FAAO, & Arthur B. Epstein, OD, FAAO Most of us, including many clinicians, can get lost in the forest for the trees when trying to understand Dry Eye and Dry Eye Flares. With up to 70-80% of Dry Eye patients in some practices suffering from Dry Eye Flares, it's important for practitioners to understand where these numbers are coming from, and what they can do to lower them. In this podcast, Dr. Art Epstein, OD, FAAO, joins Walt Whitley, OD, MBA, FAAO, to discuss the importance of communication surrounding triggers and treatment options with patients, as well as keeping practitioners up-to-date with the current literature to better understand the pathophysiology of the condition.

EPISODE 3: To Be A Dry Eye Detective: Patient Identification Through Clinical Experience Preeya Gupta, MD, & Mitchell A. Jackson, MD The dry eye population can present with different challenges along with varied intensity and frequency of Dry Eye Flares, among other differences that can affect how ophthalmologists formulate their treatment strategy. In this episode, Mitchell A. Jackson, MD, joins Preeya Gupta, MD to discuss how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%* can be part of an appropriate treatment plan for many of their dry eye patients—from the non-compliant patient to the patient using artificial tears still suffering from Dry Eye Flares to the pre-op patient preparing for cataract or refractive surgery.

EPISODE 3: To Be A Dry Eye Detective: Patient Identification Through Clinical Experience Walt Whitley, OD, MBA, FAAO, & Scott Hauswirth, OD, FAAO The dry eye population can present with different challenges along with varied intensity and frequency of Dry Eye Flares, among other differences that can affect how optometrists formulate their treatment strategy. In this episode, Scott Hauswirth, OD, FAAO, joins Walt Whitley, OD, MBA, FAAO to discuss how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%* can be part of an appropriate treatment plan for many of their dry eye patients—from the noncompliant patient to the patient using artificial tears still suffering from Dry Eye Flares to co-managing the pre-op patient preparing for cataract or refractive surgery—by asking proactive questions.

Walt Whitley, OD, MBA, FAAO, & Selina McGee, OD, FAAO The journey of the dry eye patient can be challenging. They often go to multiple practitioners and try several at-home remedies in an attempt to have their condition taken seriously and get some relief. In this podcast, Selina McGee, OD, FAAO, joins Walt Whitley, OD, MBA, FAAO to discuss the importance of building trust to empower dry eye patients in order to confidently take back control of their condition, as well as how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%*—the first FDA-approved steroid for the short-term treatment (up to two weeks) of the signs and symptoms of DED—and its AMPPLIFY® technology may benefit their patients.

Preeya Gupta, MD, & Cynthia Matossian, MD, FACS, ABES The journey of the dry eye patient can be challenging. They often go to multiple practitioners and try several at-home remedies in an attempt to have their condition taken seriously and get some relief. In this podcast, Cynthia Matossian, MD, FACS, ABES joins Preeya Gupta, MD to discuss the importance of building trust to empower dry eye patients to take back control in order to better manage their condition, as well as how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%*—the first FDA-approved steroid for the short-term treatment (up to two weeks) of the signs and symptoms of DED—and its AMPPLIFY® technology may benefit their patients.

This podcast session will explore a fresh approach to treating Dry Eye Disease (DED) and the challenges faced by your current and future patients. We are all aware that MDs play an important role as first responders in how care is delivered to DED patients. At Kala, we have discovered through extensive market research that Dry Eye Disease does not always present as continuous signs and symptoms, rather it is punctuated by exacerbating episodes or “speed bumps” called Dry Eye Flares. Join Preeya Gupta, MD in his conversation with Lisa Nijm, MD as they navigate Dry Eye Flares along with the role of inflammation in identifying patients who might benefit from a different treatment of DED.

This podcast session will explore a fresh approach to treating Dry Eye Disease (DED) and the challenges faced by your current and future patients. We are all aware that ODs play an important role as first responders in how care is delivered to DED patients. At Kala, we have discovered through extensive market research that Dry Eye Disease does not always present as continuous signs and symptoms, rather it is punctuated by exacerbating episodes or “speed bumps” called Dry Eye Flares. Join Walt Whitley, OD, MBA, FAAO in his conversation with Margie Recalde, OD, FAAO as they navigate Dry Eye Flares along with the role of inflammation in identifying patients who might benefit from a different treatment of DED.